Teva Pharmaceuticals has reported a robust performance for Q3 2024, demonstrating significant revenue and earnings growth while making solid progress across its pipeline and core business segments.
Teva Delivers Strong Q3 Results with Revenue Growth, Pipeline Progress and Upgraded Guidance
Teva Delivers Strong Q3 Results with Revenue…
Teva Delivers Strong Q3 Results with Revenue Growth, Pipeline Progress and Upgraded Guidance
Teva Pharmaceuticals has reported a robust performance for Q3 2024, demonstrating significant revenue and earnings growth while making solid progress across its pipeline and core business segments.